Faranoxi

The aim of the present study was to evaluate the antitumor activity of faranoxi experimentally and clinically. Faranoxi is a derivative of chloroethylaminophenylacetic acid containing a cytostatic group modified by oxygen in its structure. It has a broad spectrum of antitumor activity in experimental studies. One hundred eighty-eight patients with different types of malignancies were included in clinical studies. At a dosage of 90-120 mg/m2 a day for 12-15 days faranoxi is relatively well tolerated. Clinical studies demonstrate the antitumor activity of faranoxi against melanoma, lymphoma and rectal cancer. It should be noted that primary melanoma was less responsive to faranoxi compared to lymphoid metastases. Using the combination regimen FDV (faranoxi, deticene, vincristine) as treatment of melanoma, partial remission was achieved in up to 50% of the cases. Clinical trials are ongoing.

The experiments were carried out using hematoporphyrin (Hpo), dimethoxyhematoporphyrin (DMHp) and an alkylating antitumor drug pharanoxi phosphas (Ph).The influence of Hp or DMHp on the acute toxicity of Pp was investigated in toxicol. experimentsChanges of mice body mass, mass of spleen and percentage of mice death were observedThe influence of Hp or DMHp on the toxic effect of Pp and ⁶⁰Co irradiation on the organism was studied in therapeutical experimentsChanges of mice mass, survival time of animals, mass of spleen and volume of ascites were the main criteria.Our toxicol. exptl. data revealed that under the influence of Hp and DMHp the acute toxicity of Pp decreased.In our therapy studies, only Hp had a pos. influence on the toxic effect of the alkylating agent Pp and ⁶⁰Co irradiation on the organism.